Franck Perraudin: Lp(a) Lowering Alone May Not Be Enough
Franck Perraudin, VP – Cardiovascular TA Head International Commercial and Launch Strategy at Novartis, shared a post on LinkedIn:
“The Phase 3 HORIZON Trial showed that reductions in Lipoprotein(a) (Lp(a)) did not meet its primary endpoint of reducing a composite of cardiovascular death.
This is for sure a set back, a deception for ASCVD patients with elevated Lp(a) and yet it need to be regarded as a scientific progress in understanding human biology and cardiovascular risk factors.
Lp(a) remains a well-established, inherited cardiovascular risk factor.
For patients, the message is clear: cardiovascular risk remains multifactorial, and optimizing LDL‑C and comorbidities is more important than ever.
- Lp(a) lowering alone may not be enough — residual risk from LDL‑C, inflammation, diabetes, hypertension, and obesity still drives events.
- LDL‑C long term management and optimization remains the strongest proven lever for reducing ASCVD risk.
- Comorbidity control (diabetes, blood pressure, weight, kidney disease, smoking) is decisive for long‑term outcomes.
The Opportunity Ahead:
Pelacarsen’s results don’t close the door on Lp(a) therapies — they sharpen our focus.
Patients benefit most when LDL‑C is aggressively lowered, risk factors are controlled, and new therapies are integrated thoughtfully as evidence evolves.
This post reflects my personal views and interpretation of recent scientific data. It is not an official Novartis communication and does not represent the position, strategy, or endorsement of my employer.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?